{"id":507822,"date":"2021-06-29T15:41:14","date_gmt":"2021-06-29T19:41:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/"},"modified":"2021-06-29T15:41:14","modified_gmt":"2021-06-29T19:41:14","slug":"iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/","title":{"rendered":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN CARLOS, Calif., June  29, 2021  (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET.<\/p>\n<p>To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2989712. The live webcast can be accessed in the Investors section of the Company\u2019s website at <a href=\"http:\/\/www.iovance.com\" rel=\"nofollow noopener\" target=\"_blank\">www.iovance.com<\/a>. The archived webcast will also be available for one year in the Investors section at <a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow noopener\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Iovance Biotherapeutics, Inc.<\/strong><\/p>\n<p>Iovance Biotherapeutics\u00a0aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient\u2019s own immune cells to attack cancer. TIL cells are extracted from a patient\u2019s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company\u2019s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow noopener\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <strong>Iovance Biotherapeutics, Inc<\/strong>:<br \/>Sara Pellegrino, IRC<br \/>Vice President, Investor Relations &amp; Public Relations<br \/>650-260-7120 ext. 264<br \/><a href=\"mailto:Sara.Pellegrino@iovance.com\" rel=\"nofollow noopener\" target=\"_blank\">Sara.Pellegrino@iovance.com<\/a><\/p>\n<p>\n        <strong>Solebury Trout:<\/strong><br \/>\n        <br \/>Zara Lockshin\u00a0(media)<br \/>646.378.2960<br \/><a href=\"mailto:zlockshin@soleburytrout.com\" rel=\"nofollow noopener\" target=\"_blank\">zlockshin@soleburytrout.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1789c83b-e3e1-47fb-ae5d-b8d47274d1d0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2989712. The live webcast can be accessed in the Investors section of the Company\u2019s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com. About\u00a0Iovance Biotherapeutics, Inc. Iovance Biotherapeutics\u00a0aims to improve patient care by making T cell-based &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-507822","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2989712. The live webcast can be accessed in the Investors section of the Company\u2019s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com. About\u00a0Iovance Biotherapeutics, Inc. Iovance Biotherapeutics\u00a0aims to improve patient care by making T cell-based &hellip; Continue reading &quot;Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T19:41:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET\",\"datePublished\":\"2021-06-29T19:41:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/\",\"name\":\"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=\",\"datePublished\":\"2021-06-29T19:41:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/","og_locale":"en_US","og_type":"article","og_title":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET - Market Newsdesk","og_description":"SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2989712. The live webcast can be accessed in the Investors section of the Company\u2019s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com. About\u00a0Iovance Biotherapeutics, Inc. Iovance Biotherapeutics\u00a0aims to improve patient care by making T cell-based &hellip; Continue reading \"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-29T19:41:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET","datePublished":"2021-06-29T19:41:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/"},"wordCount":327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/","name":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=","datePublished":"2021-06-29T19:41:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MjU3OCM0Mjc1MTUzIzIwMTkxOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-host-conference-call-and-webcast-to-discuss-clinical-data-for-ln-145-in-non-small-cell-lung-cancer-on-june-29-2021-at-430pm-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/507822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=507822"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/507822\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=507822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=507822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=507822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}